Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Drozd-Sokołowska, Joanna  [Clear All Filters]
2023
Gurnari C, Robin M, Godley LA, Drozd-Sokołowska J, Włodarski MW, Raj K, Onida F, Worel N, Ciceri F, Carbacioglu S, et al. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023.
Sośnia O, Pruszczyk K, Danecki M, Wąsik-Szczepanek E, Tryc-Szponder J, Iskierka-Jażdżewska E, Majeranowski A, Krzemień H, Bołkun Ł, Paszkiewicz-Kozik E, et al. Richter transformation - retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group. Leuk Lymphoma. 2023:1-12.
2021
Drozd-Sokołowska J, Waszczuk-Gajda A, Topczewska M, Manko J, Hus I, Szmigielska-Kapłon A, Nowicki M, Grygoruk-Wiśniowska I, Krawczyk-Kuliś M, Romejko-Jarosińska J, et al. Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group. J Clin Apher. 2021.
2020
Waszczuk-Gajda A, Małyszko J, Vesole DH, Feliksbrot-Bratosiewicz M, Skwierawska K, Krzanowska K, Kobylińska K, Biecek P, Snarski E, Rodziewicz-Lurzyńska A, et al. Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant. Transplant Proc. 2020.
2019
Drozd-Sokołowska J, Zaucha JMaciej, Żółtak T, Jamroziak K, Grzybowska-Izydorczyk O, Witkowska M, Waszczuk-Gajda A, Kaźmierczak M, Szczepaniak A, Subocz E, et al. Hodgkin lymphoma transformation of chronic lymphocytic leukemia - a real life data from the Polish Lymphoma Research Group. Hematol Oncol. 2019.
Długosz-Danecka M, Hus I, Puła B, Jurczyszyn A, Chojnacki T, Blajer-Olszewska B, Drozd-Sokołowska J, Raźny M, Romejko-Jarosińska J, Taszner M, et al. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis. Pharmacol Rep. 2019;71(3):473-477.